FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074387411> ?p ?o ?g. }

• W2074387411 endingPage "223" @default.
• W2074387411 startingPage "213" @default.
• W2074387411 abstract "The toxicologic, biologic, and clinical effects of recombinant interleukin-2 (IL-2) were tested in 25 patients with cancer. Escalating doses from 103 to 107 U/m2 per day were given by either daily bolus injection (BI) or continuous infusion (CI) for 7 consecutive days. Dose-limiting toxicities included a decline in performance status, systolic hypotension, and fever, which reversed promptly with discontinuation of therapy. The maximum tolerated dose of IL-2 by BI for 7 days was 3 X 106 U/m2 per day and for CI was 106 U/m2 per day. Significant changes in the number, phenotype, and function of circulating peripheral blood lymphocytes occurred at doses > 106 U/m2 per day by both administration schedules. With the initiation of therapy, a decline in the number of circulating peripheral blood lymphocytes (PBL) was seen in patients treated by either BI or CI. Additionally, the in vitro cytotoxic activity of these PBL against K562 was markedly decreased. Within 24 h of completing BI or CI, a rebound increase in the number of circulating PBL was seen. The phenotype of the circulating PBL after completion of treatment showed a significant (p > 0.05) increase in the numbers of OKT-3+, OKT-8+, OKT-10+, OK-Ia+, OKMI +, and OKT-11 + for patients treated by CI. Those patients treated by BI had a significant increase in Ia+ and OKT-10+ cells. At IL-2 doses >105 U/m2 per day, the PBL obtained following treatment with rIL-2 demonstrated in vitro cytotoxic capacity against K562 target cells that was significantly enhanced over pretreatment levels. This study demonstrates that IL-2 can be given by CI or BI in a non-ICU setting with acceptable dose-dependent toxicity. Upon completion of treatment an increase in the number of activated cells could be detected. Although no clinical responses occurred, the generation of endogenous activated PBL capable of enhanced cytotoxicity is encouraging. Future studies will explore the use of multiple courses of treatment with IL-2 to determine if therapeutic efficacy can be accomplished." @default.
• W2074387411 created "2016-06-24" @default.
• W2074387411 creator A5011569932 @default.
• W2074387411 creator A5031061622 @default.
• W2074387411 creator A5031252498 @default.
• W2074387411 creator A5041474042 @default.
• W2074387411 creator A5056737382 @default.
• W2074387411 creator A5070467855 @default.
• W2074387411 creator A5073727127 @default.
• W2074387411 date "1989-01-01" @default.
• W2074387411 modified "2023-09-23" @default.
• W2074387411 title "Phase 1 Clinical Trial of Recombinant Interleukin-2: A Comparison of Bolus and Continuous Intravenous Infusion" @default.
• W2074387411 cites W1970871013 @default.
• W2074387411 cites W1977096306 @default.
• W2074387411 cites W1978350435 @default.
• W2074387411 cites W20021324 @default.
• W2074387411 cites W2014113952 @default.
• W2074387411 cites W2036275492 @default.
• W2074387411 cites W2047786043 @default.
• W2074387411 cites W2049822454 @default.
• W2074387411 cites W2130537353 @default.
• W2074387411 cites W2167266648 @default.
• W2074387411 cites W2168025297 @default.
• W2074387411 cites W2179970611 @default.
• W2074387411 cites W2255455702 @default.
• W2074387411 cites W2260574412 @default.
• W2074387411 cites W2322553446 @default.
• W2074387411 cites W2399766730 @default.
• W2074387411 doi "https://doi.org/10.3109/07357908909039840" @default.
• W2074387411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2790538" @default.
• W2074387411 hasPublicationYear "1989" @default.
• W2074387411 type Work @default.
• W2074387411 sameAs 2074387411 @default.
• W2074387411 citedByCount "30" @default.
• W2074387411 crossrefType "journal-article" @default.
• W2074387411 hasAuthorship W2074387411A5011569932 @default.
• W2074387411 hasAuthorship W2074387411A5031061622 @default.
• W2074387411 hasAuthorship W2074387411A5031252498 @default.
• W2074387411 hasAuthorship W2074387411A5041474042 @default.
• W2074387411 hasAuthorship W2074387411A5056737382 @default.
• W2074387411 hasAuthorship W2074387411A5070467855 @default.
• W2074387411 hasAuthorship W2074387411A5073727127 @default.
• W2074387411 hasConcept C104317684 @default.
• W2074387411 hasConcept C126322002 @default.
• W2074387411 hasConcept C185592680 @default.
• W2074387411 hasConcept C2777371288 @default.
• W2074387411 hasConcept C2778690821 @default.
• W2074387411 hasConcept C2778715236 @default.
• W2074387411 hasConcept C40767141 @default.
• W2074387411 hasConcept C43376680 @default.
• W2074387411 hasConcept C55493867 @default.
• W2074387411 hasConcept C71924100 @default.
• W2074387411 hasConcept C90924648 @default.
• W2074387411 hasConcept C98274493 @default.
• W2074387411 hasConceptScore W2074387411C104317684 @default.
• W2074387411 hasConceptScore W2074387411C126322002 @default.
• W2074387411 hasConceptScore W2074387411C185592680 @default.
• W2074387411 hasConceptScore W2074387411C2777371288 @default.
• W2074387411 hasConceptScore W2074387411C2778690821 @default.
• W2074387411 hasConceptScore W2074387411C2778715236 @default.
• W2074387411 hasConceptScore W2074387411C40767141 @default.
• W2074387411 hasConceptScore W2074387411C43376680 @default.
• W2074387411 hasConceptScore W2074387411C55493867 @default.
• W2074387411 hasConceptScore W2074387411C71924100 @default.
• W2074387411 hasConceptScore W2074387411C90924648 @default.
• W2074387411 hasConceptScore W2074387411C98274493 @default.
• W2074387411 hasIssue "3" @default.
• W2074387411 hasLocation W20743874111 @default.
• W2074387411 hasLocation W20743874112 @default.
• W2074387411 hasOpenAccess W2074387411 @default.
• W2074387411 hasPrimaryLocation W20743874111 @default.
• W2074387411 hasRelatedWork W1999880542 @default.
• W2074387411 hasRelatedWork W2026915063 @default.
• W2074387411 hasRelatedWork W2028728636 @default.
• W2074387411 hasRelatedWork W2040559992 @default.
• W2074387411 hasRelatedWork W2052631352 @default.
• W2074387411 hasRelatedWork W2083242203 @default.
• W2074387411 hasRelatedWork W2352946368 @default.
• W2074387411 hasRelatedWork W2595635579 @default.
• W2074387411 hasRelatedWork W2766844642 @default.
• W2074387411 hasRelatedWork W2899396768 @default.
• W2074387411 hasVolume "7" @default.
• W2074387411 isParatext "false" @default.
• W2074387411 isRetracted "false" @default.
• W2074387411 magId "2074387411" @default.
• W2074387411 workType "article" @default.